IXICO plc Contract win for new neuroinflammatory disorder (0509Z)
19 Mayo 2021 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 0509Z
IXICO plc
19 May 2021
IXICO plc
("IXICO" or the "Company")
Contract win for new neuroinflammatory disorder
Contract extends IXICO's CNS franchise to include a further new
disease indication
IXICO plc (AIM:IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been selected by a
current biopharmaceutical client to provide neuroimaging services
for a Phase III clinical trial . Following on from the recent
contract win announcement made on 28(th) April for an acute
ischemic stroke study, today's contract announcement is for a
Neuroinflammatory disorder study, extending IXICO's CNS franchise
to include a further new disease indication. In addition to
deepening the commercial relationship with this client, the
additional contract highlights the Company's strategic momentum in
diversifying across new neurological therapeutic areas.
Neuroinflammatory disorders such as multiple sclerosis (MS)
represent an important area of research within CNS, with an active
and growing number of new clinical trials anticipated. The new
Phase III trial will be conducted across 50 sites in North America
and Europe and is worth in excess of GBP0.5m over 4 years.
Lammert Albers, Chief Commercial Officer of IXICO,
commented:
" IXICO is delighted to be awarded the contract for this new
study. By bringing together our Company's proven therapeutic
expertise, advanced AI analytics and robust operational
infrastructure, IXICO will enable this existing biopharmaceutical
client to accelerate R&D decision making, de-risk clinical
research and maximise the value of their CNS drug development
pipelines. We are proud to support all sponsors in their tireless
efforts to bring potential treatments to patients suffering from
neurological disorders and the new award reflects the confidence
customers place in IXICO as the trusted leading neuroimaging
partner for their Phase III CNS studies."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTGZGMKVRRGMZM
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024